Novavax | NVAX - Selling And Administration Expenses


Novavax reported $25.53M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Adma Biologics USD 20.19M 2.86M Dec/2025
Agenus USD 10.56M 13.04M Dec/2025
AstraZeneca USD 5.06B 455M Mar/2026
BioCryst Pharmaceuticals USD 95.78M 12.77M Dec/2025
Cassava Sciences USD 6.66M 1.24M Dec/2025
Geron USD 35.42M 6.24M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
MannKind USD 54.08M 4.33M Mar/2026
Merck USD 2.67B 180M Mar/2026
Minerva Neurosciences USD 2.48M 58.79K Sep/2024
Moderna USD 173M 135M Mar/2026
Novartis USD 3.44B 132M Dec/2025
Novavax USD 25.53M 1.34M Dec/2025
Pfizer USD 2.92B 1.16B Mar/2026
Sanofi EUR 2.33B 419M Mar/2026
Sarepta Therapeutics USD 54.03M 51.35M Mar/2026
TG Therapeutics USD 73.14M 22.42M Mar/2026